

# 2024 Current Fiscal Year Report: Advisory Committee to the Director, National Institutes of Health

Report Run Date: 04/26/2024 03:54:32 PM

## 1. Department or Agency

Department of Health and Human Services

## 2. Fiscal Year

2024

## 3. Committee or Subcommittee

Advisory Committee to the Director, National  
Institutes of Health

## 3b. GSA

## Committee

## No.

775

## 4. Is this New During Fiscal Year?

No

## 5. Current Charter

05/31/2023 05/31/2025

## 6. Expected Renewal Date

## 7. Expected Term Date

## 8a. Was Terminated During Fiscal Year?

No

## 8b. Specific Termination Authority

## 8c. Actual Term Date

## 9. Agency Recommendation for Next Fiscal Year

Continue

## 10a. Legislation Req to Terminate?

Not Applicable

## 10b. Legislation Pending?

Not Applicable

## 11. Establishment Authority Authorized by Law

## 12. Specific Establishment Authority

42 USC 217a

## 13. Effective Date

11/17/1962

## 14. Committee Type

Continuing

## 14c. Presidential?

No

## 15. Description of Committee Scientific Technical Program

Advisory Board

## 16a. Total Number of Reports

No Reports for  
this Fiscal Year

## 17a. Open

0 17b. Closed0 17c. Partially Closed0 Other Activities0 17d. Total0

## Meetings and Dates

No Meetings

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00
<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

**20a. How does the Committee accomplish its purpose?**

During this reporting period the committee approved one new request for access to HeLa genome sequencing data. At the November 3, 2022 meeting, the committee heard presentations on the proposed New Framework for Peer Review Criteria; the proposed ACD Working Group on Re-envisioning NIH supported Postdoctoral Training Post Doc Working Group; and the Proposed ACD Working Group on Catalyzing the Development and Use of Alternative Methods to Advance Biomedical Research. At the December 8-9, 2022, meeting the committee discussed the

following issues: Advanced Research Projects Agency (ARPA-H) Update; Perspectives on the Current Cooperation with NIH and Priorities for the Future; Pandemic Preparedness and Response: Lessons from COVID-19; Proposed Changes to Peer Review Criteria; Proposed ACD Novel Alternative Methods Working Group; Proposed ACD Post-Doc Working Group; HeLA Genome Data Access Working Group: Data Access Requests; Update on Assessing the Public Health Threat of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)—NIH RECOVER Initiative; NIH Efforts in Support of Open Data; Update from the ACD Working Group on Diversity: Disability Subgroup Report; and UNITE Update. At the December 2022 meeting, two new working groups (WGs) were introduced: the ACD WG on Novel Alternative Methods and the ACD WG on Postdoctoral Training. Additionally, in December 2022, the Advisory Committee to the Director approved the report and recommendations from the Individuals with Disabilities subgroup of the ACD WG on Diversity regarding updating the NIH's mission statement to eliminate potentially ableist language, establishing an NIH Office of Disability Research and an NIH Disability Equity and Access Coordinating Committee, and ensuring anti-ableism are core components of all NIH DEIA efforts. At the June 8-9, 2023 meeting, the committee received updates from the HeLA Genome Data Access Working Group; ACD Working Group on Catalyzing the Development and Use of Novel Alternative Methods to Advance Biomedical Research; and the ACD Working Group on Re-envisioning NIH-Supported Postdoctoral Training. The June 2023 meeting also included discussions on the following topics: NIH Public Access Plan; Cancer Moonshot; Addressing the Mental Health Crisis through

Research; Addressing the Public Health Threat of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). The ACD heard presentations regarding the Foundation for the National Institutes of Health (FNIH); Clinical Trial Stewardship; Accessibility Update; and NIH-wide Collaborative Initiative on Climate Change and Health. One closed session meeting was conducted on June 8, 2023, to facilitate review of the proposed FY23 Pay Plan for the Regenerative Medicine Innovation Project (RMIP) in accordance with the 21st Century Cares Act.

**20b. How does the Committee balance its membership?**

During the past year, the Advisory Committee to the Director, NIH, consisted of members selected from among authorities who are knowledgeable in the fields of research pertinent to the NIH mission and individuals selected from the academic and private sector research community, as well as individuals selected from the general public.

**20c. How frequent and relevant are the Committee Meetings?**

The Committee met three times (11/3/2022; 12/8-9/2022; 6/8-9/2023) during this reporting period and held multiple working group meetings on the following dates: 3/11/2023, 4/8/2023, 5/4/2023, 6/1/2023, 7/8/2023, 8/12/2023, 8/21-22/2023, 9/9/2023, and 10/14/2023.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The members of the Advisory Committee to the Director have experience, current expertise, and abilities pertinent to the NIH mission that cannot be obtained from NIH staff or from other established sources.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

The June 8-9, 2023 meeting of the Committee was partially closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**21. Remarks**

Members: The terms for Shelley Berger, Roberta Brinton and Barbara Wold changed due to administrative extensions. As such, their terms of service end dates are different than what was reported on the FY22 ACR. Ex Officio Members: Dr. Lawrence Tabak's title was updated from Performing the Duties of the NIH Director to Acting Director, NIH this fiscal year. Members Rotating Off/Vacancies: Eight members rotated off (Shelley Berger, Roberta Brinton, Wendy Chapman, Rebekah Drezek, Kristina Johnson, Dina Katabi, Judith Kimble, and Barbara Wold). In addition, there are 6 vacancies. This is why the Charter states 21 potential members, but this ACR lists 15. DFO/Committee Decision Maker: Based on the assignment of responsibilities within the Office of the Director, NIH, the positions of designated federal officer and the committee decision maker are held by the same person. Reports: The working group report was deliberated on and approved by the ACD.

**Designated Federal Officer**

# TARA A. SCHWETZ Acting Principal Deputy

## Director

Committee Members	Start	End	Occupation	Member Designation
BUTTE, ATUL	06/05/2022	12/31/2026	PRISCILLA CHAN AND MARK ZUCKERBERG DISTINGUISHED PROFESSOR OF PEDIATRICS, BIOENGINEERING AND THERAPEUTIC SCIENCES, AND EPIDEMIOLOGY AND BIOSTATISTICS, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO VIRGINIA AND D.K. LUDWIG PROFESSOR OF CANCER RESEARCH, PROFESSOR OF DERMATOLOGY AND GENETIC, DEPARTMENT OF DERMATOLOGY, STANFORD UNIVERSITY SCHOOL OF MEDICINE K. RANGA RAMA KRISHNAN ENDOWED ASSOCIATE PROFESSOR, DUKE UNIVERSITY MEDICAL SCHOOL PROFESSOR OF EPIDEMIOLOGY AND MEDICINE, MAILMAN SCHOOL OF PUBLIC HEALTH, COLUMBIA UNIVERSITY	Special Government Employee (SGE) Member
CHANG, HOWARD	06/05/2022	12/31/2026		Special Government Employee (SGE) Member
DZIRASA, KAFUI	05/22/2022	12/31/2026		Special Government Employee (SGE) Member
EL-SADR, WAFAA	06/05/2022	12/31/2026		Special Government Employee (SGE) Member

GRAHAM, GARTH	06/05/2022	12/31/2026	DIRECTOR AND GLOBAL HEAD OF HEALTHCARE AND PUBLIC HEALTH, GOOGLE	Special Government Employee (SGE) Member
KIMBALL, ALEXANDRA	06/06/2021	12/31/2024	PRESIDENT AND CHIEF EXECUTIVE OFFICER, HARVARD MEDICAL FACULTY PHYSICIANS, BETH ISRAEL DEACONESS MEDICAL CENTER	Special Government Employee (SGE) Member
TABAK, LAWRENCE	12/20/2021	01/20/2025	ACTING DIRECTOR, NIH	Ex Officio Member

**Number of Committee Members Listed: 7**

### **Narrative Description**

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The Advisory Committee to the Director, NIH, advises the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, NIH, on matters related to planning, execution, conduct, support, and evaluation of biomedical research, medical science, and biomedical communications. The Advisory Committee to the Director has addressed numerous issues in these areas including: Diversity, Equity, Inclusion and Accessibility Initiatives; Researching COVID to Enhance Recovery Initiative; Advanced Research Projects Agency for Health (ARPA-H); Climate Change and Health; UNITE Initiative; Catalyzing the Development and Use of Novel Alternative Methods to Advance Biomedical Research; NIH Public Access Plan; Re-envisioning NIH-Supported Postdoctoral Training; Pandemic Preparedness and Response; Addressing Mental Health Crisis through Research; and Addressing the Public Health Threat of Post-Acute Sequelae of SARS-CoV-2 Infection.

**What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input checked="" type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input type="checkbox"/>

**Outcome Comments**

NA

**What are the cost savings associated with this committee?**

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

**Cost Savings Comments**

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**



### Number of Recommendations Comments

During this reporting period there were a total of 4 recommendations made by the Committee.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

0%

### % of Recommendations Fully Implemented Comments

Due to the large breadth and complexity of the recommendations made by this committee, NIH staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

0%

### % of Recommendations Partially Implemented Comments

NA

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

### Agency Feedback Comments

Information is provided to the public at each meeting. The public can view information related to the Committee through the committee's official website.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

### Action Comments

The Advisory Committee to the Director, NIH, will provide advice to the Secretary of Health and Human Services (Secretary), the Assistant Secretary for Health, and the Director, National Institutes of Health (NIH), on matters related to planning, execution, conduct, support, and evaluation of biomedical research, medical science, and biomedical communications.

### Is the Committee engaged in the review of applications for grants?

Yes

What is the estimated Number of grants reviewed for approval 13

What is the estimated Number of grants recommended for approval 13

What is the estimated Dollar Value of grants recommended for approval \$8,000,000

### Grant Review Comments

NA

### How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

### Access Comments

IC Committee Management Officer 240-276-6420